Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics : HC Wainwright Adjusts VYNE Therapeutics' Price Target to $11 from $14, Keeps Buy Rating

05/07/2021 | 01:37pm EDT


© MT Newswires 2021
All news about VYNE THERAPEUTICS INC.
10/21VYNE THERAPEUTICS : Announces Formation of Scientific Advisory Board
AQ
10/19VYNE THERAPEUTICS : Enrolls First Patient in Trial of FMX114 to Treat Atopic Dermatitis; S..
MT
10/19VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of..
PU
10/19VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/19VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of..
AQ
10/19VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment o..
CI
10/05VYNE THERAPEUTICS : Partner Cutia Therapeutics Enrolls First Patient in Late-Stage Acne Dr..
MT
10/05VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 ..
CI
09/20VYNE THERAPEUTICS : to Present at the Cantor Fitzgerald Investment Conference
AQ
09/08VYNE THERAPEUTICS : to Present at the H.C. Wainwright Annual Investment Conference
AQ
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 18,2 M - -
Net income 2021 -70,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,85x
Yield 2021 -
Capitalization 58,7 M 58,7 M -
Capi. / Sales 2021 3,22x
Capi. / Sales 2022 8,18x
Nbr of Employees 106
Free-Float 87,2%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,14 $
Average target price 6,67 $
Spread / Average Target 485%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-81.96%59
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979